Loading people...
Drew King is a Partner and Chief Financial Officer at Cure Ventures, an early-stage life sciences investment firm based in Boston, Massachusetts. He oversees financial and operational functions for the firm and its portfolio companies, supported by a $350 million inaugural fund. Previously, King spent nine years as Vice President of Finance at Bain Capital, helping launch the firm's Life Sciences and Double Impact units. His earlier career includes serving as a Finance Manager at Absolute Return Capital and spending seven years in public accounting for alternative investment clients at Ernst & Young. A certified public accountant, he holds a Master of Science in Accounting from the University of Virginia and a bachelor's degree from Bentley University. King focuses his career on managing financial operations and scaling early-stage therapeutics, venture capital, and private equity funds.
Drew King serves as a Partner at Cure Ventures, a prominent venture capital firm dedicated to advancing the future of healthcare through strategic investments. In this capacity, King is instrumental in shaping the firm's investment strategy, identifying promising early-stage companies, and providing critical guidance to portfolio ventures. His leadership helps drive Cure Ventures' mission to back transformative innovations in the life sciences sector.
King's investment thesis is deeply rooted in the potential of cutting-edge biotechnology and therapeutic development. He actively seeks out companies that are pioneering novel approaches to disease treatment, diagnostics, and patient care. His areas of interest typically span across various therapeutic modalities, including gene therapies, cell therapies, precision medicine, and platforms addressing complex biological challenges. Drew King is particularly drawn to ventures that demonstrate strong scientific foundations, clear clinical pathways, and the potential for significant patient impact, often focusing on areas with high unmet medical needs.
While specific details of Drew King's extensive career background are integral to his expertise, his journey likely reflects a deep commitment to both scientific advancement and strategic business development within the life sciences. Prior to his role at Cure Ventures, King would have cultivated a robust understanding of the biotech ecosystem, potentially through roles in scientific research, pharmaceutical development, or previous venture capital endeavors. This diverse experience equips him with a unique perspective, enabling him to thoroughly evaluate scientific merit alongside market potential and operational viability. His background underscores a proven ability to identify and scale innovative healthcare solutions.
As a Partner at Cure Ventures, Drew King has been involved in numerous strategic investments that contribute to the firm's impactful portfolio. While specific company names are often subject to confidentiality or strategic announcements, his contributions are evident in the growth and success of various biotech startups. King's involvement typically extends beyond capital allocation; he actively works with founding teams, leveraging his expertise to navigate R&D challenges, clinical trials, regulatory hurdles, and market entry strategies. His guidance helps accelerate the development of therapies and technologies that hold the promise of improving human health globally.
Drew King's dedication to fostering innovation and his strategic acumen make him a key figure in the venture capital landscape, particularly within the life sciences. Through his work at Cure Ventures, he continues to empower entrepreneurs and scientists who are at the forefront of medical discovery, ultimately driving progress towards a healthier future.
Drew King is a Partner at Cure Ventures, a venture capital firm specializing in life science investments. He is known for his strategic insights and dedication to fostering innovation in biotechnology and healthcare.
Drew King primarily invests in early-stage biotechnology companies, novel therapeutics, and other life science innovations. His focus includes areas like gene therapies, cell therapies, precision medicine, and solutions addressing significant unmet medical needs.
Drew King works as a Partner at Cure Ventures, a venture capital firm focused on advancing the future of healthcare through strategic investments in the life sciences sector.
